Domainex and SpiroChem Enter a Fragment Drug Discovery Partnership
Image credit: Domainex
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Domainex Ltd, an integrated provider of drug discovery services that has established a world-leading position in fragment-based drug discovery and SpiroChem AG, a premium chemical and services companies specialized in the design and synthesis of proprietary collections of sp3-rich molecular fragments and associated synthetic capabilities, have established a strategic fragment drug discovery collaboration that they will co-promote globally.
Under the terms of the agreement, Domainex will enrich its existing fragment collection with a diverse set of SpiroChem fragments that it will screen with its highly efficient and cost-effective FragmentBuilder platform. The SpiroChem-sourced fragments will provide unique chemical diversity, particularly in terms of three-dimensional chemotypes. The companies will work together to offer hit expansion services on the resulting fragment hits to their clients in a seamless manner, leveraging the combined expertise of their respective chemistry teams, supported as required with biophysical and biochemical assays and structural biology.
Domainex Chief Operating Officer, Tom Mander commented ‘Since our investment in automated microscale thermophoresis instrumentation from Nanotemper Technologies back in 2016, we have seen a strong uptake of our integrated FragmentBuilder services and have initiated numerous fragment drug discovery partnerships with organisations across the world. We are delighted to be announcing this new partnership with SpiroChem, an organisation that also has a strong reputation for innovation and delivery. The additional diversity that their fragments bring to our existing collection will further strengthen and differentiate our world-leading position in fragment-based drug discovery. It will give our clients a truly unique approach to identify well-characterised and attractive chemical starting points for subsequent optimisation into drug candidates’.
SpiroChem Chief Executive Officer, Thomas Fessard added ‘Fragment-based lead discovery has demonstrated its strength in delivering new leads for drug targets over the past few years and we have seen a booming demand for our fragment collections. Our carefully designed libraries stand out of commercial “flat-land” libraries and add this 3D-character that medicinal chemists are looking for. Obviously, with higher structural complexity, fragment evolution capabilities require special synthetic skills that SpiroChem is mastering, thereby allowing for efficient fragment evolution and exploration of their chemical space. We are thrilled to collaborate with Domainex, and be able to offer a comprehensive discovery proposal, from library design and screening to efficient downstream medicinal chemistry services, all the way to candidate selection’.
Under the terms of the agreement, Domainex will enrich its existing fragment collection with a diverse set of SpiroChem fragments that it will screen with its highly efficient and cost-effective FragmentBuilder platform. The SpiroChem-sourced fragments will provide unique chemical diversity, particularly in terms of three-dimensional chemotypes. The companies will work together to offer hit expansion services on the resulting fragment hits to their clients in a seamless manner, leveraging the combined expertise of their respective chemistry teams, supported as required with biophysical and biochemical assays and structural biology.
Domainex Chief Operating Officer, Tom Mander commented ‘Since our investment in automated microscale thermophoresis instrumentation from Nanotemper Technologies back in 2016, we have seen a strong uptake of our integrated FragmentBuilder services and have initiated numerous fragment drug discovery partnerships with organisations across the world. We are delighted to be announcing this new partnership with SpiroChem, an organisation that also has a strong reputation for innovation and delivery. The additional diversity that their fragments bring to our existing collection will further strengthen and differentiate our world-leading position in fragment-based drug discovery. It will give our clients a truly unique approach to identify well-characterised and attractive chemical starting points for subsequent optimisation into drug candidates’.
SpiroChem Chief Executive Officer, Thomas Fessard added ‘Fragment-based lead discovery has demonstrated its strength in delivering new leads for drug targets over the past few years and we have seen a booming demand for our fragment collections. Our carefully designed libraries stand out of commercial “flat-land” libraries and add this 3D-character that medicinal chemists are looking for. Obviously, with higher structural complexity, fragment evolution capabilities require special synthetic skills that SpiroChem is mastering, thereby allowing for efficient fragment evolution and exploration of their chemical space. We are thrilled to collaborate with Domainex, and be able to offer a comprehensive discovery proposal, from library design and screening to efficient downstream medicinal chemistry services, all the way to candidate selection’.
